

19.11.2018

BSE Limited
 Department of Corporate Relationship
 1st Floor, New Trade Ring, Rotunda Building
 Phiroze Jeejeebhoy Towers
 Dalal Street, Mumbai- 400001
 Scrip Code : 524742

By BSE Listing

National Stock Exchange of India Ltd.,
 Department of Corporate Services
 Exchange Plaza, 5th Floor,
 C-1, Block G, Bandra Kurla Complex,
 Bandra (E), Mumbai – 400 051
 Scrip Code : CAPLIPOINT.

By NEAPS

Dear Sirs,

SUB: INTIMATION UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

The Board of Directors of the Company at their meeting held today, subject to obtaining approval of the shareholders and requisite approvals from statutory and regulatory authorities, if any, approved the slump sale of business undertaking of the Company (Regulated Markets Injectable Business, including US FDA approved Injectable plant) to its wholly owned subsidiary company which is in the process of being incorporated.

In terms of Regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, the details of sale or disposal of unit(s) or division(s) or subsidiary of the listed entity are as under:

| Sr. No. | Particulars | Details | | | |
|---------|--|-----------------------|---------------------------------------|------------------------|-----------------------|
| | | <i>(Rs. in lakhs)</i> | | | |
| | | Sr. No. | Particulars | Net Worth [#] | Turnover [#] |
| 1. | The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year* | 1. | Caplin Point Laboratories Limited | 29,560.43 | 42,657.39 |
| | | 2. | Regulated Markets Injectable Business | 9,683.51 | 711.51 |
| | | 3. | Percentage | 32.76 | 1.67 |



| | | |
|-----|---|--|
| | | *Last Financial Year: April 1, 2017 to March 31, 2018#On standalone basis |
| 2. | Date on which the agreement for sale has been entered into | The Company shall enter into a business transfer agreement with its wholly owned subsidiary (to be incorporated). The Company will intimate the stock exchanges once business transfer agreement is executed. |
| 3. | The expected date of completion of sale/disposal | Expected to be completed by January, 2019. The Company will intimate the stock exchanges once the slump sale is completed. |
| 4. | Consideration received from such sale/disposal | Regulated Markets Injectable Business of the Company to be transferred for a lump sum consideration not less than its book value (determined by an Independent Chartered Accountant). |
| 5. | Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof. | It is proposed to transfer the Regulated Markets Injectable Business to a newly incorporated company, which shall be a wholly owned subsidiary of the Company. |
| 6. | Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length" | It is proposed to transfer the Regulated Markets Injectable Business to a newly incorporated company, which shall be a wholly owned subsidiary of the Company. The consideration for slump sale shall be determined by an independent Chartered Accountant. |
| 7. | Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/ merger, shall be disclosed by the listed entity with respect to such slump sale. | Please refer points 8 to 12 below. |
| 8. | Name of the entity(ies) forming part of slump sale, details in brief such as size, turnover etc. | Standalone figures as on March 31, 2018 1. Caplin Point Laboratories Limited ('CPLL') Total Assets – Rs. 41,080.23 lakhs Net Worth – Rs. 29,560.43 lakhs Turnover – Rs. 42,657.39 lakhs 2. The acquirer shall be a newly incorporated company, which shall be a wholly owned subsidiary company of the Company. |
| 9. | Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length" | Please refer point 6 above. |
| 10. | Area of business of the entity(ies) | 1. Caplin Point Laboratories Limited Pharmaceuticals - Producing, developing and marketing wide range of generic |



| | | |
|-----|--|--|
| | | <p>formulations and branded products and exporting to overseas market.</p> <p>2. Acquirer</p> <p>Pharmaceuticals – Developing, Producing and Export of Sterile Injectable and Ophthalmic formulations, specifically to US and other regulated markets.</p> |
| 11. | Rationale for slump sale | <p>To unlock value for CPLL's Regulated Markets Injectable Business, as it is uniquely positioned to be run as a dedicated entity, targeted towards US and other regulated markets.</p> <p>To explore opportunities to attract "Capital Plus Know-how" type of strategic partnerships for Regulated Markets Injectable Business.</p> |
| 12. | Brief details of change in shareholding pattern (if any) of listed entity. | No change in the shareholding pattern of the Company. |
| 13. | In case of cash consideration – amount or otherwise share exchange ratio | Not Applicable |

The Board Meeting commenced at 11.00 AM and concluded at 2.30 PM

Thanking you,

Yours faithfully,

For **Caplin Point Laboratories Limited**


Company Secretary

